📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-29 13:21
0 analysed today
FollowTelegram
0
Today
151,859
All-time analysed
43,535
Positive
6,743
Negative
92,744
Neutral
8,769
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
4 announcements match the current filters (relevance ≥ 5).
Bacil Pharma Proposes Hike in Authorised Capital to ₹70 Cr from ₹20 Cr; AGM on Sept 23, 2026
Bacil Pharma Limited has approved the notice convening its 39th Annual General Meeting (AGM) on September 23, 2026. A key resolution includes increasing the company's Authorised Share Capital from ₹20.00 crore to ₹70.00 crore (7,00,00,000 equity shares of ₹10 each), providing substantial headroom for future equity issuances. The Board has also sought shareholder approval for redesignating Chaitali Kalpataru Shah as Managing Director until July 28, 2029, and appointing M/s Sarang Shivajirao Chavan & Associates as Statutory Auditors for four financial years.
Confidence: HIGH
What changedApproved convening the 39th AGM with key proposals to hike authorised share capital to ₹70 crore and appoint Chaitali Kalpataru Shah as Managing Director.
Why it mattersExpanding authorised share capital from ₹20 crore to ₹70 crore creates substantial headroom for fresh equity issuances, which is critical for a company with negligible operational revenue seeking revival or restructuring.
New Authorised Capital: ₹70,00,00,000Existing Authorised Capital: ₹20,00,00,000AGM Date: September 23, 2026MD Tenure Ending: July 28, 2029
📅 Short termNeutral trading expected around standard AGM administrative disclosures and governance renewals.
📈 Long termStructural revival depends on whether the enhanced share capital headroom is utilized for a viable business restart or capital induction.
⚠ Risk flags
- Zero operating revenue in recent trailing quarters
- Potential equity dilution risk from the expanded authorised share capital
- Zero promoter shareholding
Key Highlights
Proposed increase in Authorised Share Capital from ₹20.00 crore to ₹70.00 crore (7 crore equity shares of ₹10 each).
39th Annual General Meeting scheduled for Wednesday, September 23, 2026 at 3:00 PM IST via VC/OAVM.
Proposed change in designation of Chaitali Kalpataru Shah to Managing Director with tenure up to July 28, 2029.
Proposed appointment of M/s Sarang Shivajirao Chavan & Associates, Chartered Accountants, as Statutory Auditors until conclusion of 43rd AGM.
👀 What to Watch
Track voting outcomes of the AGM on September 23, 2026, and watch for subsequent corporate announcements regarding potential equity dilution or capital-raising initiatives.
Bacil Pharma reports ₹1.61 Lakh Net Loss in Q1 FY27 on Zero Operational Revenue
Bacil Pharma reported zero operational revenue for the quarter ended June 30, 2026, continuing its trend of no core business activity. The company posted a net loss of ₹1.61 lakhs, a sharp decline from a profit of ₹66.90 lakhs in the same quarter last year, as other income plummeted 91% to ₹8.91 lakhs. While Total Comprehensive Income was positive at ₹30.12 lakhs, this was entirely due to a ₹31.73 lakh gain from the fair valuation of financial assets rather than business operations.
Confidence: HIGH
What changedThe company has swung from a net profit to a net loss at the PAT level, driven by a significant reduction in non-operating 'Other Income'.
Why it mattersWith zero revenue from operations and no promoter holding, the company effectively functions as a listed shell entity with its value tied to financial asset fluctuations rather than pharmaceutical manufacturing.
Revenue from Operations: ₹0.00Net Profit/Loss (PAT): (₹1.61 Lakhs)Other Income: ₹8.91 LakhsPromoter Holding: 0.0%Market Cap: ₹23 Cr
📅 Short termThe stock is likely to remain stagnant or face pressure given the lack of fundamental business activity and the shift to a net loss.
📈 Long termLimited structural significance unless there is a major acquisition or a new promoter takes over to restart operations.
⚠ Risk flags
- Zero operational revenue
- 0% promoter holding
- Reliance on non-operating income for survival
Key Highlights
Revenue from operations remained at ₹0.00 for the quarter ended June 30, 2026.
Net loss of ₹1.61 lakhs recorded against a profit of ₹66.90 lakhs in the year-ago period.
Other income fell 91.1% YoY to ₹8.91 lakhs from ₹100.30 lakhs in June 2025.
Total Comprehensive Income of ₹30.12 lakhs was supported by a ₹31.73 lakh gain on financial asset valuation.
Promoter holding remains at 0.0%, indicating a lack of skin in the game from original founders.
👀 What to Watch
Investors should monitor for any regulatory filings regarding a change in management or business direction, as the company currently lacks any operational pharmaceutical revenue.
Bacil Pharma Q1 FY27: Zero Operational Revenue, Net Loss of ₹1.61 Lakhs
Bacil Pharma continues to report zero revenue from operations for the quarter ended June 30, 2026, consistent with its TTM performance. The company recorded a net loss of ₹1.61 lakhs at the PAT level, a sharp decline from a profit of ₹66.90 lakhs in the year-ago period. Total income, derived entirely from 'Other Income', fell 91% YoY to ₹8.91 lakhs. However, the company reported a Total Comprehensive Income of ₹30.12 lakhs, primarily driven by a ₹31.73 lakh gain on the fair valuation of financial assets.
Confidence: HIGH
What changedThe company has swung from a net profit to a net loss at the operational/PAT level, with a significant reduction in the 'Other Income' that previously supported its bottom line.
Why it mattersWith zero operational revenue and a 0% promoter holding, the company functions more as an investment vehicle than a pharmaceutical business; financial health is entirely dependent on non-core income and asset revaluation.
Revenue from Operations: ₹0.00Net Profit/Loss (PAT): ₹(1.61) LakhsOther Income: ₹8.91 LakhsTotal Comprehensive Income: ₹30.12 LakhsEPS (based on TCI): ₹0.22
📅 Short termThe lack of operational progress and the decline in other income are likely to keep the stock under pressure, especially given the recent 12-month price return of -57.1%.
📈 Long termLimited structural significance unless the company pivots to a revenue-generating model; currently lacks a functional business core.
⚠ Risk flags
- Zero operational revenue
- 0% promoter holding
- High dependence on volatile investment valuation gains
- Significant YoY decline in total income
Key Highlights
Revenue from operations remained at ₹0.00 for the quarter ended June 30, 2026.
Net Loss after tax stood at ₹1.61 lakhs compared to a profit of ₹66.90 lakhs in Q1 FY26.
Other Income dropped significantly to ₹8.91 lakhs from ₹100.30 lakhs in the corresponding quarter last year.
Total Comprehensive Income reached ₹30.12 lakhs, aided by a ₹31.73 lakh gain on fair valuation of financial assets.
Employee benefit expenses were reduced to ₹0.72 lakhs from ₹3.00 lakhs YoY.
👀 What to Watch
Investors should monitor if the company announces any plans to restart or initiate actual pharmaceutical operations, as the current valuation is supported solely by non-operational income and investment holdings.
₹50 Crore Rights Issue Approved; Two Independent Directors Resign Following BSE Query
Bacil Pharma's board has approved a significant fundraise of up to ₹50 crore through a Rights Issue of equity shares. To accommodate this, the company is increasing its authorized share capital by ₹45 crore, bringing the total to ₹65 crore. Concurrently, two independent directors, Mr. Dinesh Chander Notiyal and Ms. Avani Savjibhai Godhaniya, resigned effective July 9, 2026, citing time constraints. The exchange brief indicates these resignations follow a query raised by the BSE, adding a layer of regulatory scrutiny to the capital-raising plans.
Confidence: HIGH
What changedThe company has initiated a major capital-raising exercise while simultaneously undergoing a board restructuring following regulatory queries.
Why it mattersA ₹50 crore fundraise is substantial for a company with currently unavailable financial metrics and a low stock price, potentially leading to massive equity dilution or a total business pivot. However, the sudden exit of independent directors during a fundraise is a governance red flag.
Rights Issue Size: ₹50,00,00,000Authorized Capital Increase: ₹45,00,00,000Post-Increase Authorized Capital: ₹65,00,00,000Directors Resigned: 2
📅 Short termThe stock may experience volatility as the market weighs the benefit of the ₹50 crore cash infusion against the risks of equity dilution and the implications of the BSE query.
📈 Long termThe long-term impact depends entirely on the successful completion of the Rights Issue and the subsequent utilization of funds for business operations, which are currently not detailed.
⚠ Risk flags
- Simultaneous resignation of two independent directors
- Regulatory query from BSE mentioned in exchange brief
- Potential for significant equity dilution
- Lack of disclosed financial performance (TTM revenue/PAT n/a)
Key Highlights
Approved fundraise of up to ₹50,00,00,000 (₹50 crore) via Rights Issue to existing shareholders.
Authorized share capital increased by ₹45,00,00,000 to a new total of ₹65,00,00,000.
Resignation of 2 Independent Directors, Mr. Dinesh Chander Notiyal and Ms. Avani Savjibhai Godhaniya, effective July 9, 2026.
Appointment of Acuite Ratings & Research Limited as the Monitoring Agency for the issue.
Formation of a Rights Issue Committee chaired by Executive Director & CFO Chaitali Kalpataru Shah.
👀 What to Watch
Investors should monitor the upcoming announcement regarding the Rights Issue price and entitlement ratio, while also seeking clarity on the specific nature of the BSE query that preceded the director resignations.
